Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

cular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developme
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRese...M): Feraheme report,thesecondinamulti-phasesyndi...snewIVironproduct,Feraheme,throughthefirstsixmonth...quantitativeinformationfrom50uniqueNephrologistsan...ssesstrialanduseofFeraheme,obstaclestouse,reasonst...
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonTh...studyofitsleadproduct,PRT-201,inend-stagerenaldise...graft(AVG)creation.TheAVGstudyrepresentsProteon,ss...iouslyannouncingtheinitiationofaPhase1/2studyofPRT...sfistula(AVF)creationearlierthisyear.Proteonalsoan...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-...cedthatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagre...ionoftheproposedmergerbetweenAnesivaandArcionThera...ervotescheduledtotakeplaceatthepreviouslyannounced...ecember3,2009at9:00a.m.PSTat400OysterPoint,Suite10...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Brown professor continues debate over recovered memory 50995 1Brown professor continues debate over recovered memory 50995 2Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 1Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 2Fewer Shots Could Still Protect Kids From Pneumonia 50989 1Fewer Shots Could Still Protect Kids From Pneumonia 50989 2
... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 Interleukin Genetics,Inc....nhanced test report,format and information package...test is currently marketed under the brand name Ge...y. The new report will include quantified risk,inf...
...rd Clinical Trial,Service Unit and Epidemiological...generating results of the SEAS trial of ezetimibe ...results from the SHARP and,IMPROVE-IT trials of ez...the relevant regulatory authorities, independently...esting trials (SHARP and IMPROVE-IT) contain about...
Other Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3
(Date:11/23/2009)....G.Schwade,M.D.announcesthenewlyenhancedCyberKnife...CenterofMiami,( www.cyberknifemiami.com ). ,,...edintensedoseofradiationthatkillscancercellswithno...nlastfrom30minutestoonehour,andisusuallycompletedi...tCenterintheSoutheasternU.S.,theMiamifacilityhasle...
(Date:11/23/2009)... to treatment advances, study finds , , ...ntent of saliva changes as people age, and better ...simple test to diagnose and treat age-related dise...ins numerous proteins that play a role in digestio...ers are trying to find ways to use these proteins ...
(Date:11/23/2009)...the brain is regulated by a peptide known as C3a, ...into nerve cells and is also important for the mig..., reveals new research from the Sahlgrenska Academ...ugh the research has been carried out using mice a... for human beings, which could be given to patient...
(Date:11/23/2009)...partment of Agriculture (USDA) has awarded a two-y...rsity of Minnesota to complete sequencing the geno.... The funding will be used by the Turkey Genome Se...ing using next-generation sequencing platforms, as... functions in the final genome sequence by use of ...
(Date:11/23/2009)...Call/--AnnTaylorStoresCorp.announcedtodaythatitwil...sandGivingcampaign,aholidayfundraisingandawareness...armarksthethirdyearthatAnnTaylor,throughitsANNCARE...mpaignwhereweofferourshoppersanopportunitytohelpsa...hisholidayseason.ClientswhoshopatAnnTaylor,Loft,An...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2
...600 injuries were reported by the US consumer prod...n previously thought and raising concerns. These ...y are the target market for these wheeled shoes. T...crowded malls and playgrounds. Scott Wolfson...
... no good reason to deny insurers access to genetic...bate published in this weeks BMJ. Only if...nformation can we reasonably stop them seeking gen... be able to differentiate premiums according to ve...
...esearch suggests that cannabis, also known as mari...gies and autoimmune disorders that occur when bod... Researchers led by Andreas Zimmer, at the U.... However, the researchers warned that peo...
... on Thursday received 15 million dollars worth of ...nment to bolster its fight against HIV and AIDS, o...ates will provide Zimbabwe with anti-retroviral dr...US government, which has frosty relations with the...
... TATA company, is in negotiations with Prof Vijay ...ttached to the University of Arkansas, to start p... the final stages. The deal is yet to be finalized...ter (HiDEC) and Neurosurgery Research Programme in...
...llion Euro research project, European Lifestyles a...for Europes four regional seas. As part o...rom 28 institutions from 15 European countries, fo...oss-cutting environmental issues: habitat change, ...
Other Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Zimbabwe Receives 15m Dollars of AIDS Drugs from US 2Health News:Titan may Produce Glucose Watches Soon 2Health News:Dire Future Predicted for Europe's 4 Seas 2
7.75mm diameter Corneal Trephine Blades
6.5mm diameter Corneal Trephine Blades
5.5mm diameter Corneal Trephine Blades
7.50mm Open Trephine Handle
Medicine Products: